Current treatment options for restless legs syndrome

Thomas C. Wetter, Juliane Winkelmann, Ilonka Eisensehr

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Restless legs syndrome (RLS) is a common but often underdiagnosed neurological disorder characterised by an imperative desire to move the extremities associated with paraesthesias, motor restlessness, worsening of symptoms at rest in the evening or at night and, as a consequence, sleep disturbances particulary. Additionally, most patients with RLS have periodic limb movements during sleep and relaxed wakefulness. The aetiology of RLS remains unknown. Treatment of RLS is generally symptomatic, a causal therapy is possible only in the secondary forms. Dopaminergic agents including levodopa and dopamine agonists such as pergolide, pramipexole, cabergoline and ropinirole are regarded as the treatment of choice for idiopathic RLS, however, the development of augmentation of symptoms, especially under levodopa therapy, may be a major problem. Except in special circumstances, opioids and anticonvulsants such as gabapentin or benzodiazepines, are regarded as second-line treatment. In secondary RLS, the underlying illness should first be treated, although dopaminergic drugs may also be helpful.

Original languageEnglish
Pages (from-to)1727-1738
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number10
StatePublished - Oct 2003
Externally publishedYes


  • Anticonvulsants
  • Augmentation
  • Benzodiazepines
  • Dopamine agonists
  • Levodopa
  • Opioids
  • Periodic limb movements
  • Restless legs syndrome


Dive into the research topics of 'Current treatment options for restless legs syndrome'. Together they form a unique fingerprint.

Cite this